Clinical progress of bendamustine in the treatment of lymphoma and leukemia
10.3760/cma.j.issn.1009-9921.2013.08.004
- VernacularTitle:苯达莫司汀治疗淋巴瘤及白血病的研究进展
- Author:
Shaoping LIANG
;
Huaqing WANG
- Publication Type:Journal Article
- Keywords:
Bendamustine;
Lymphoma;
Leukemia,lymphocyte,chronic;
Multiple myeloma
- From:
Journal of Leukemia & Lymphoma
2013;22(8):456-461,465
- CountryChina
- Language:Chinese
-
Abstract:
Bendamustine is a kind of nitrogen mustard derivatives consisting of a 2-chloroethylamine alkylating group and a benzimidazole ring.This special structure grants its anti-cancer mechanism different from other common alkylating agents with double function.Since approved,bendanustine has been widely used to treat henatologic malignancies and solid tumors such as breast cancer.In 2008,the FDA approved bendamustine injection for the treatment of chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma.In recent years,scholars in China and abroad have carried out a series of clinical researches on single bendamustine and bendamsutine combinational chemotherapy,especially in hematologic malignancies,which obtained certain clinical efficacy.In this paper,the pharmacological actions,pharmacokinetics and clinical progress of bendamustine in lymphoma and leukemia are reviewed.
